報價延遲最少15分鐘:2025/01/12 05:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
29.49 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.54/3.20
|
|
企業價值
17.78B
|
| 資產負債 |
|
每股賬面淨值
15.46
|
| 現金流量 |
|
現金流量率
0.18
|
| 損益表 |
|
收益
2.35B
|
|
每股收益
5.23
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 05:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |